Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma
Stegmann, D.A.
Medizinische Monatsschrift für Pharmazeuten 39(4): 142-147
2016
ISSN/ISBN: 0342-9601 PMID: 27209894 Document Number: 688057
Despite advances in drug therapy of the orphan disease multiple myeloma, patients relapse or become refractory to first-line therapy, and the disease remains incurable. Therefore, histone deacetylase inhibitors have emerged as a new class of anti-myeloma drugs, with synergistic results on progression free survival when given in combination to current first-line therapy. Histone deacetylase inhibitors influence gene expression of target genes. Based on results of an extensive multicenter phase III trial, panobinostat was approved by the FDA in February 2015 as the first histone deacetylase inhibitor for the treatment of multiple myeloma. In Europe, panobinostat received marketing authorization by August 2015.